Bleeding risk in IPF patients treated with different anticoagulants:Real world data from the European MultiPartner IPF Registry (EMPIRE)
Bildiriler > Özet Bildiri · 2018
Yazarlar: Abigel Margit Kolonics-Farkas, Martina Sterclova, Nesrin MOĞULKOÇ BISHOP, Jan Kus, Veronika Mueller, Marta Hajkova, Dragana Jovanovic, Jasna Tekavec-Trkanjec, Mordechai Kramer, Michal Svoboda, Marketa Janotova, Martina Vasakova
Idiopathic interstitial pneumonias, Fransa, Uluslararası, Sözlü Sunum, Özet Bildiri, 2018-2018, Wos, cilt 52, ss PA2205-PA2205
DOI: 10.1183/13993003.congress-2018.pa2205
Özet
EMPIRE is an international, multicentre registry of idiopathic pulmonary fibrosis (IPF) patients in Central and Eastern Europe. Two approved treatments are available, nintedanib and pirfenidone. Nintedanib may increase the risk of bleeding and patients treated with anticoagulants were excluded from clinical trials. Our aim was to examine bleeding risk with current treatments in EMPIRE patients. IPF patients (N=1528) were divided into four groups: Group A (no anticoagulant or antiplatelet therapy; N=984); Group B (anticoagulant treatment; N=131); Group C (antiplatelet treatment; N=371); Group D (anticoagulant and antiplatelet treatment; N=42). Nintedanib was used in 203 (13.7%), pirfenidone in 283 (19.1%) patients. FVC was similar in all groups; only 5-10% of patients had FVC<50%. Group A patients were significantly younger as compared to Groups B and C, and had significantly fewer comorbidities as compared to all other groups (p<0.001). Mortality was significantly higher in Group B vs. A (32.8% and 22.2% respectively; p=0.029). Nintedanib treatment was significantly more frequent in Group A (15.9%), as compared to Group B (6.3%; p=0.007) and lower in Groups D (12.2%) and C (10.9%). Bleeding as adverse event occurred only in 1 patient treated with nintedanib in Group A, B and D. Pirfenidone treatment was more evenly balanced in all groups: most commonly used in Group D (24.4%) and similar in all other groups (A: 19.1%; B: 21.9%; C: 17.5%). In EMPIRE, patients on anticoagulant medications are less frequently receiving nintedanib therapy, which might be due to the mode of action of nintedanib. Overall, the incidence of bleeding events was very low.